130 related articles for article (PubMed ID: 38861154)
1. Charting the Etanercept Journey: Tracing Cost Dynamics in Poland's Off-Patent Market from Reference Drug Rivalry to Biosimilar Monopoly.
Stajszczyk M; Batko K; Żuber ZM; Kwiatkowska B; Krajewska-Włodarczyk M; Batko B
BioDrugs; 2024 Jun; ():. PubMed ID: 38861154
[TBL] [Abstract][Full Text] [Related]
2. Competition in the off-patent medicine market in Spain: The national reference pricing system versus the regional system of tendering for outpatient prescription medicines in Andalusia.
Casanova-Juanes J; Mestre-Ferrandiz J; Espín-Balbino J
Health Policy; 2018 Dec; 122(12):1310-1315. PubMed ID: 30389186
[TBL] [Abstract][Full Text] [Related]
3. The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland.
Luukkanen SV; Tolonen HM; Airaksinen M; Saarukka LSM
BioDrugs; 2022 Jul; 36(4):537-547. PubMed ID: 35793041
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of etanercept originator and biosimilar for treating rheumatoid arthritis: implications for cost-savings.
Deakin CT; Littlejohn GO; Griffiths H; Ciciriello S; O'Sullivan C; Smith T; Youssef P; Bird P;
Intern Med J; 2024 May; 54(5):795-801. PubMed ID: 38009675
[TBL] [Abstract][Full Text] [Related]
5. Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis.
Vandenplas Y; Simoens S; Van Wilder P; Vulto AG; Huys I
Front Pharmacol; 2021; 12():644187. PubMed ID: 33953678
[No Abstract] [Full Text] [Related]
6. Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends.
Car E; Vulto AG; Houdenhoven MV; Huys I; Simoens S
Front Pharmacol; 2023; 14():1151764. PubMed ID: 37153785
[No Abstract] [Full Text] [Related]
7. Cost-effectiveness Analysis of Treatment Sequence Initiating With Etanercept Compared With Leflunomide in Rheumatoid Arthritis: Impact of Reduced Etanercept Cost With Patent Expiration in South Korea.
Park SK; Park SH; Lee MY; Park JH; Jeong JH; Lee EK
Clin Ther; 2016 Nov; 38(11):2430-2446.e3. PubMed ID: 27771177
[TBL] [Abstract][Full Text] [Related]
8. Off-Patent Biologicals and Biosimilars Tendering in Europe-A Proposal towards More Sustainable Practices.
Barbier L; Simoens S; Soontjens C; Claus B; Vulto AG; Huys I
Pharmaceuticals (Basel); 2021 May; 14(6):. PubMed ID: 34073861
[TBL] [Abstract][Full Text] [Related]
9. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Yıldız M; Osman E
Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
[TBL] [Abstract][Full Text] [Related]
10. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.
Dickson SR; Kent T
JAMA Netw Open; 2021 Nov; 4(11):e2133451. PubMed ID: 34779844
[TBL] [Abstract][Full Text] [Related]
11. Pharmacoeconomic evaluation of costs of rheumatoid arthritis therapy with selected biological treatment.
Kowalik K; Węgierska M; Barczyńska T; Jeka S
Reumatologia; 2018; 56(6):340-345. PubMed ID: 30647479
[TBL] [Abstract][Full Text] [Related]
12. The impact of pharmaceutical tendering on prices and market concentration in South Africa over a 14-year period.
Wouters OJ; Sandberg DM; Pillay A; Kanavos PG
Soc Sci Med; 2019 Jan; 220():362-370. PubMed ID: 30513486
[TBL] [Abstract][Full Text] [Related]
13. Projected US savings from biosimilars, 2021-2025.
Mulcahy A; Buttorff C; Finegold K; El-Kilani Z; Oliver JF; Murphy S; Jessup A
Am J Manag Care; 2022 Jul; 28(7):329-335. PubMed ID: 35852882
[TBL] [Abstract][Full Text] [Related]
14. Biosimilar competition: Early learning.
Frank RG; Shahzad M; Kesselheim AS; Feldman W
Health Econ; 2022 Apr; 31(4):647-663. PubMed ID: 35023225
[TBL] [Abstract][Full Text] [Related]
15. Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2-Biosimilar and Originator Etanercept in the Outpatient Setting.
Moorkens E; Simoens S; Troein P; Declerck P; Vulto AG; Huys I
BioDrugs; 2019 Jun; 33(3):299-306. PubMed ID: 30945206
[TBL] [Abstract][Full Text] [Related]
16. Real-world effectiveness and persistence of reference etanercept versus biosimilar etanercept GP2015 among rheumatoid arthritis patients: A cohort study.
Carballo N; Pérez García C; Grau S; Monfort J; Durán-Jordà X; Echeverría-Esnal D; Ferrández O
Front Pharmacol; 2022; 13():980832. PubMed ID: 36263118
[TBL] [Abstract][Full Text] [Related]
17. Regional tenders on biosimilars in Italy: an empirical analysis of awarded prices.
Curto S; Ghislandi S; van de Vooren K; Duranti S; Garattini L
Health Policy; 2014 Jun; 116(2-3):182-7. PubMed ID: 24602376
[TBL] [Abstract][Full Text] [Related]
18. Long-term Medicaid excess payments from alleged price manipulation of generic lorazepam.
Bian B; Gorevski E; Kelton CM; Guo JJ; Martin Boone JE
J Manag Care Pharm; 2012 Sep; 18(7):506-15. PubMed ID: 22971204
[TBL] [Abstract][Full Text] [Related]
19. A health economic guide to market access of biosimilars.
Simoens S; Vulto AG
Expert Opin Biol Ther; 2021 Jan; 21(1):9-17. PubMed ID: 33206021
[No Abstract] [Full Text] [Related]
20. Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database.
Stajszczyk M; Obarska I; Jeka S; Batko B
Ann Rheum Dis; 2023 Sep; 82(9):1171-1180. PubMed ID: 37328194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]